Contribute Try STAT+ Today

Rise and shine, everyone, the middle of the week is already here, which means we have managed to survive this far. And this calls for celebration, yes? So please join us as we hoist another cup of delicious stimulation — our choice today is mountain blueberry. Remember, no prescription is required, so no need to calculate a rebate. Meanwhile, here are a few items of interest. Have a grand day, and drop us a line if you hear something saucy. …

Johnson & Johnson (JNJ) expects to release results from its Covid-19 vaccine trial in as little as two weeks, but unanticipated manufacturing delays will prevent the vaccine from getting out the door and into arms until April, The New York Times reports. Federal officials have been told that the company has fallen as much as two months behind the original production schedule and will not catch up until the end of April, when it was supposed to have delivered more than 60 million doses of the single-shot vaccine.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.